首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1623208

血液製劑的全球市場規模:各產品類型，各最終用途，各地區，範圍及預測

Global Blood Product Market Size By Product Type (Platelets, Fresh Frozen Plasma (FFP)), By End-Use (Hospitals, Blood Station), By Geographic Scope And Forecast

出版日期: 2024年07月08日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

血液製品的市場規模及預測

2024 年血液製品市場規模價值為 381.6 億美元，預計到 2031 年將達到 544.3 億美元，在 2024-2031 年預測期內的複合年增長率為 4.54%。血液相關疾病的盛行率不斷上升以及對血液相關產品的需求正在推動血液產品市場的成長。此外，老年人口的增加也大大推動了血液製品市場的成長。全球血液製品市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

全球血液製品市場的定義

血液製品是從捐贈者體內提取並輸給患者的血液成分或部分。並非所有患者都需要輸全血；許多患者只需要輸注血液中的某些成分。為了適應這些情況，某些血液成分被從全血中分離出來。血液產品包括血小板、紅血球 (RBC)、白血球 (WBC)、新鮮冷凍血漿 (FFP)、凝血因子等。根據您的症狀，我們將給您注射特定的血液製品。

血液是人體必需的連接液體，為身體器官提供營養和氧氣。血液製品分為血液成分製品及血漿製品。血液成分包括紅血球、冷沉澱和新鮮冷凍血漿，而血漿成分包括白蛋白、凝血因子和免疫球蛋白。血漿衍生產品受《藥品事務法》管轄，必須由執業醫師開立處方，因為現在全血輸血很少見，而血液成分在給患者輸血時變得更加重要。

血液的每個成分都必須在相同的條件下儲存，例如紅血球必須在冰箱的特定溫度下儲存。根據血液安全和品質法規，採集的血液必須以可讀和條碼格式標記適當的資訊。從捐贈者身上抽取 405-495 毫升血液，放入 63 毫升檸檬酸磷酸鹽葡萄糖和抗凝血劑。捐贈的全血經過過濾以去除白血球。

全球血液製品市場概況

白血病、癌症、末期腎衰竭等血液疾病的發生率增加，其他需要輸血的疾病也需要輸血，此外，創傷和任何促使大量出血的嚴重損傷也需要輸血。此外，血液製品市場受到主要市場參與者的推動，這些參與者提供實驗室試劑、篩檢設備以及對捐贈血液進行檢測的系統。

此外，全球老年人口的增加以及政府對血液篩檢的措施和法規預計將促進血液製品市場的發展。此外，大眾對捐血的認知也是加速市場成長的因素之一。另一方面，先進血液採集的高成本和熟練實驗室技術人員的短缺限制了血液製品市場的成長。

Blood Product Market size was valued at USD 38.16 Billion in 2024 and is projected to reach USD 54.43 Billion by 2031, growing at a CAGR of 4.54% during the forecast period 2024-2031. The growing prevalence of blood-related disorders and demand for blood-related products are boosting the growth of the Blood Product Market. In addition, the increasing geriatric population is prominently driving the growth of the Blood Product Market. The Global Blood Product Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Blood Product Market Definition

Blood Product is any component or part of blood that is collected from a donor for substituting the same in patients. Not every patient requires a transfusion of whole blood, many only require certain components of blood for transfusion. To meet such cases, several blood components are separated from the whole blood. The blood products include platelets, red blood cells (RBCs), white blood cells (WBCs), fresh frozen plasma (FFP), clotting factors, and many others. Depending on the condition, an individual is administered a particular blood product.

Blood is an essential connective fluid of the body that supplies nutrients and oxygen to the organs of the body. Blood products are classified as blood components and plasma-derived products. Blood components include red cells, cryoprecipitate, and fresh frozen plasma while plasma components include albumin, coagulation factors, and immunoglobulin. Plasma derivatives come under the medicines act, which must be prescribed by licensed practitioners as whole blood transfusion is rare now, and blood components are making more sense while transferring to the patient.

Each component of blood must be stored under identical conditions such as red blood cells must be stored in the refrigerator at a specified temperature. as per blood safety and quality, regulation collected blood must be labeled with appropriate information that must be in readable form and barcoded form. 405-495mL of blood can be collected from one donor and then it is collected in 63 mL of citrate phosphate dextrose ad anticoagulant. All donated whole blood was filtered to remove white blood cells.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Product Market Overview

Blood is an essential component of the body. increasing blood disorders and other medical conditions such as leukemia, cancer, and the end stage of renal disorders require blood transfusion other than this, trauma and any kind of serious injury in which there is huge blood loss demand blood transfusion.in addition, some major surgeries also lead to blood loss thus, there has been more demand for blood and plasma components. Furthermore, the Blood Product Market is prominently driven by key market players that offers reagent for testing, and screening devices along with a system to perform a test of blood that is being donated.

Moreover, the increasing geriatric population across the globe and government initiatives and regulations for blood screening are anticipated to boost the Blood Product Market. Also, awareness about blood donation among people is another factor responsible for accelerating market growth. On the other side, the high cost associated with advanced blood collection and the lack of skilled laboratory people is restricting the growth of the Blood Product Market.

Global Blood Product Market: Segmentation Analysis

The Global Blood Product Market is segmented on the basis of Product Type, End-Use, and Geography.

Blood Product Market, By Product Type

Platelets
Fresh Frozen Plasma (FFP)
Red Blood Cells (RBCs)
White Blood Cells (WBCs)
Others

Based on Product Type, the market is bifurcated into Platelets, Fresh Frozen Plasma (FFP), Red Blood Cells (RBCs), White Blood Cells (WBCs), and Others. The red blood cell segment is expected to hold the largest share in the market as it is given to newborns, sickle cell anemia patients, and emergency transfusions during pregnancy, trauma patients. Increasing such medical conditions is driving the growth of the market.

Blood Product Market, By End-Use

Hospital
Blood Station
Others

Based on End-Use, the market is bifurcated into Hospital, Blood Station, and Others. Blood station is expected to hold the largest market share due to a surge in the number of blood station and a large amount of blood is received in blood station by donors. in addition, the rise in the demand for blood and plasma is driving the demand for blood components.

Blood Product Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, The Global Blood Product Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The largest share in the market will be dominated by North America Blood Product Market growth in North America is driven by many factors such as the easy availability of reagents, consumables, and systems required for blood collection and the rise in awareness of blood donation in the region.

Key Players

The "Global Blood Product Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
CSL, Octapharma AG, Kedrion S.p.A, Mitsubishi Tanabe Pharma Corporation, and BPL Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

Partnerships, Business Expansion, and Product Launch
In Dec 2020, CSL Behring enters into a collaboration agreement with Biopole. The collaboration aims to connect the Biopole ecosystem and its start-ups to this global biotechnology. CSL and its REI team will highlight their key goal of increasing global collaboration on external early projects to feed and support growth through this partnership.
In March 2021, Mitsubishi Tanabe Pharma America, Inc. (MTPA) recently announced that Mitsubishi Tanabe Pharma Holdings America, Inc. (MTHA) intends to establish a new NeuroDiscovery Lab in Cambridge, Mass., a biotechnology hub in the United States. The research facility will serve as a North American hub for identifying and collaborating on precision medicine and new drug development for central nervous system (CNS) diseases, specifically amyotrophic lateral sclerosis (ALS).
In Aug 2021, BPL Introduces An Innovative Line Of Smartly Designed Consumer Electronics Intended To Satisfy Even The Most Strict Customers.
In Aug 2021, Reliance Retail will manufacture BPL and Kelvinator products. Reliance Retail has obtained the right to manufacture and sell consumer durable goods under the BPL and Kelvinator brands. The move will also allow Reliance Retail to enter the electrical market, and the agreement with BPL will be announced soon, while the agreement with Kelvinator has already been announced.
Mergers and Acquisitions
In Jan 2022, Kedrion will be acquired by Permira, which has merged with BPL and plans to take a minority stake in the combined company.

1 INTRODUCTION OF GLOBAL BLOOD PRODUCT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BLOOD PRODUCT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BLOOD PRODUCT MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Platelets
5.3 Fresh Frozen Plasma (FFP)
5.4 Red Blood Cells (RBCs)
5.5 White Blood Cells (WBCs)
5.6 Others

6 GLOBAL BLOOD PRODUCT MARKET, BY END-USE

6.1 Overview
6.2 Hospital
6.3 Blood Station
6.4 Others

7 GLOBAL BLOOD PRODUCT MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL BLOOD PRODUCT MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 CSL
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Octapharma AG
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Kedrion S.p.A
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Mitsubishi Tanabe Pharma Corporation
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 BPL Inc.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments